Vasodilator Therapy in Heart Failure

Pathophysiological Rationale for Vasodilators

In the setting of heart failure, a low cardiac output triggers compensatory mechanisms, predominantly the activation of the sympathetic nervous system (catecholamines) and the renin-angiotensin-aldosterone system (RAAS).
These neurohormonal pathways inappropriately induce excessive arteriolar and venous vasoconstriction.
Arteriolar constriction increases systemic vascular resistance (afterload), which directly increases the workload of the failing myocardium.
Venoconstriction decreases venous capacitance and increases venous return (preload), which elevates the filling pressures of the ventricles and exacerbates pulmonary and systemic congestion.
Vasodilator therapy aims to counteract these maladaptive compensatory mechanisms.
By reducing systemic vascular resistance and decreasing venous tone, vasodilators effectively reduce the work of the heart, lower left ventricular end-diastolic pressure (LVEDP), improve tissue oxygen delivery, and alleviate dyspnea and pulmonary congestion.

Clinical Indications and Diagnostic Triggers

Specific indications for the use of vasodilators in pediatric heart failure include acute mitral or aortic regurgitation, ventricular dysfunction resulting from myocarditis, anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA), dilated cardiomyopathy, and the early postoperative period following congenital heart surgery.
The initiation of vasodilator therapy is often guided by specific findings on diagnostic investigations:
- Echocardiography: Findings prompting afterload reduction include a dilated left ventricle, depressed left ventricular ejection fraction (e.g., $\leq$ 40%), or the presence of severe eccentric regurgitant jets across the mitral or aortic valves.
- Electrocardiogram (ECG): Patients may display sinus tachycardia, non-specific ST-T wave changes, or specific ischemic changes such as deep 'q' waves in leads I, aVL, and V4-V6 with ST-segment elevation (classical for ALCAPA-induced failure).
- Cardiac Catheterization: Hemodynamic profiles indicating the need for vasodilators include an elevated pulmonary capillary wedge pressure (PCWP), a high systemic vascular resistance (SVR), and an elevated left ventricular end-diastolic pressure (LVEDP) in the setting of a reduced cardiac index.

Pharmacological Agents and Management

Drug Class	Specific Agents and Dosing	Mechanism of Action and Clinical Management
Angiotensin-Converting Enzyme (ACE) Inhibitors	Captopril: 0.1–0.5 mg/kg/dose PO q6–24 h (Infants/Children)Enalapril: 0.05–0.1 mg/kg/day PO (Infants/Children)	Inhibits the conversion of Angiotensin I to Angiotensin II, providing potent afterload reduction and preventing aldosterone-mediated salt and water retention. Represents the most clinically useful class of oral vasodilators. First dose should be 1/4 of the calculated target dose to prevent first-dose hypotension. Requires monitoring of serum creatinine and electrolytes every 1-2 weeks initially due to the risk of hyperkalemia and acute kidney injury. Must be withheld during dehydration and avoided in neonates.
Angiotensin Receptor Blockers (ARBs)	Losartan: 0.75 mg/kg/day PO (up to 50 mg/day)	Competitively inhibits the binding of Angiotensin II to the AT1 receptor. Utilized primarily as an alternative afterload-reducing agent if persistent dry cough necessitates the discontinuation of ACE inhibitors.
Angiotensin Receptor-Neprilysin Inhibitor (ARNI)	Sacubitril/Valsartan: Dosed based on weight tiers (e.g., <40 kg, 40-50 kg, >50 kg)	Sacubitril inhibits neprilysin, preventing the degradation of B-type natriuretic peptide (BNP) and promoting vasodilation and natriuresis, while valsartan blocks the RAAS pathway. Approved for pediatric patients older than 1 year of age with systemic left ventricular systolic dysfunction.
Direct Vasodilators (Parenteral)	Sodium Nitroprusside: 0.5–8 $μ$ g/kg/min IV continuous infusion	Acts directly on both venous and arterial smooth muscle, providing rapid reduction in preload and afterload in acute, critical care settings. Because of its potent effects, continuous arterial blood pressure monitoring is mandatory to prevent sudden hypotension. Prolonged use (especially in renal failure) requires monitoring of serum thiocyanate and cyanide levels to prevent toxicity (manifesting as metabolic acidosis, psychosis, and weakness).
Inodilators	Milrinone: 0.25–1 $μ$ g/kg/min IV continuous infusion	Phosphodiesterase type-3 inhibitor that increases intracellular cAMP, providing both positive inotropic support and profound systemic and pulmonary vasodilation. Highly effective in managing low-output states in the intensive care unit without significantly increasing myocardial oxygen demand.
Nitrates	Nitroglycerin: 0.25–10 $μ$ g/kg/min IV continuous infusion	Acts as a preferential venodilator, primarily reducing venous return (preload) to decrease pulmonary congestion and ventricular filling pressures.